Effect of long-term pretreatment with atrvastatin on patients undergoing the second percutaneous coronary intervention

Objective To investigate the potential effects of taking atrvastain more than 6 months on CD40L expression and myocardial damage of patients undergoing percutaneous coronary intervention(PCI) once again.Methods A total of 90 patients with unstable angina were randomized into groups of pretreatment with continuous atrvastatin(6 months before the second PCI,atrvastatin group) and without atrvastatin(control group).Creatine kinase-MB(CK-MB),tropoinin I(cTnI),and CD40L level were determined at 12,24 and 48 hours post the second PCI.Results Before PCI,low level of CD40L was observed in the atrvastatin group.CK-MB level was significantly reduced in the atrvastatin group(P 0.05) 12 and 24 hours after PCI,cTnIs were significantly decreased in the atrvastatin group(P 0.05)12,24 and 48 hours after PCI;CD40 L was significantly reduced in the atrvastatin group(P 0.05) 24 hours after the PCI.In the control group,the CK-MB upgraded obviously(P 0.05),and CD40 expression was markedly upregulated at 12 and 24 hours after the operation.Conclusion Long-term pretreatment with atrvastatin may alleviate myocardial damage of patients undergoing PCI and decrease soluble CD40L amplification.